Literature DB >> 34597139

Pseudogene-mediated DNA demethylation leads to oncogene activation.

Junsu Kwon1, Yanjing V Liu1, Chong Gao2, Mahmoud A Bassal1,3, Adrianna I Jones3, Junyu Yang2, Zhiyuan Chen2, Ying Li1, Henry Yang1, Leilei Chen1, Annalisa Di Ruscio4,5,6, Yvonne Tay1,7, Li Chai2, Daniel G Tenen1,3,4.   

Abstract

Pseudogenes, noncoding homologs of protein-coding genes, once considered nonfunctional evolutionary relics, have recently been linked to patient prognoses and cancer subtypes. Despite this potential clinical importance, only a handful of >12,000 pseudogenes in humans have been characterized in cancers to date. Here, we describe a previously unrecognized role for pseudogenes as potent epigenetic regulators that can demethylate and activate oncogenes. We focused on SALL4, a known oncogene in hepatocellular carcinoma (HCC) with eight pseudogenes. Using a locus-specific demethylating technology, we identified the critical CpG region for SALL4 expression. We demonstrated that SALL4 pseudogene 5 hypomethylates this region through interaction with DNMT1, resulting in SALL4 up-regulation. Intriguingly, pseudogene 5 is significantly up-regulated in a hepatitis B virus model before SALL4 induction, and both are increased in patients with HBV-HCC. Our results suggest that pseudogene-mediated demethylation represents a novel mechanism of oncogene activation in cancer.

Entities:  

Year:  2021        PMID: 34597139     DOI: 10.1126/sciadv.abg1695

Source DB:  PubMed          Journal:  Sci Adv        ISSN: 2375-2548            Impact factor:   14.136


  3 in total

1.  Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.

Authors:  Junyu Yang; Chong Gao; Miao Liu; Yao-Chung Liu; Junsu Kwon; Jun Qi; Xi Tian; Alicia Stein; Yanjing V Liu; Nikki R Kong; Yue Wu; Shenyi Yin; Jianzhong Xi; Zhiyuan Chen; Kalpana Kumari; Hannan Wong; Hongbo Luo; Leslie E Silberstein; Julie A I Thoms; Ashwin Unnikrishnan; John E Pimanda; Daniel G Tenen; Li Chai
Journal:  Cancer Res       Date:  2021-09-30       Impact factor: 13.312

2.  Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome.

Authors:  Juliane Grimm; Mascha Binder
Journal:  Signal Transduct Target Ther       Date:  2022-08-09

Review 3.  SALL4: An Intriguing Therapeutic Target in Cancer Treatment.

Authors:  Shiva Moein; Daniel G Tenen; Giovanni Amabile; Li Chai
Journal:  Cells       Date:  2022-08-20       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.